Poster

The Efficacy and Safety of Esketamine Nasal Spray Versus Quetiapine Extended Release Over 32 Weeks in Patients With Treatment-Resistant Depression: A Subgroup Analysis of the ESCAPE-TRD Study

Abstract: Objective: ESCAPE‑TRD (NCT04338321), a randomized, open-label, rater-blinded, trial demonstrated benefits for esketamine nasal spray (ESK) versus quetiapine extended release (QX...

08/20/2024

Long-term Safety, Tolerability, and Effectiveness of TV-46000—a Long-Acting Subcutaneous Antipsychotic (LASCA)—in Patients With Schizophrenia: A Phase 3, Randomized, Double-Blind Study (SHINE)

Abstract: Background: TV-46000 is a long-acting subcutaneous antipsychotic (LASCA) that combines risperidone and an innovative, copolymer-based drug delivery technology. In the RISE study...

08/20/2024

The SOLARIS Protocol: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Assessing Safety and Efficacy of TV-44749 (Olanzapine for Extended-Release Injectable Suspension Use) in Adults With Schizophrenia

Abstract: Background: Among patients with schizophrenia, nonadherence to oral antipsychotics increases relapse risk. Adherence may be improved with long-acting injectable (LAI) antipsycho...

08/20/2024

Matching-adjusted Indirect Treatment Comparison and Network Meta-Analysis of Zuranolone to Standard-of-care Antidepressant Therapies for the Acute Treatment of Adults with Major Depressive Disorder

Abstract: Background: Major depressive disorder (MDD) is a debilitating disease for which there is an unmet need for rapid-acting treatments. Zuranolone is an investigational oral, once-d...

08/20/2024

Total Cost of Care Following First-Line Antidepressant Treatment Failure Among Patients With Major Depressive Disorder in the United States

Abstract: OBJECTIVES: To evaluate total all-cause healthcare costs among US patients diagnosed with major depressive disorder (MDD) who failed first-line antidepressant treatment (ADT). ...

08/20/2024

Medication Adherence and Healthcare Resource Utilization in South Carolina Medicaid Beneficiaries with Schizophrenia or Schizoaffective Disorder: Long-acting Injectable vs. Oral Antipsychotics

Abstract: Background: Schizophrenia requires long-term treatment with antipsychotics; however, poor adherence to antipsychotic treatment can result in increased healthcare resource utiliz...

08/20/2024

Transitioning Patients to Long-Acting Injectable Antipsychotics: Attitudes and Perceptions of US Clinicians Based on a Hypothetical Case (Results from the DECIDE Survey)

Abstract: Background: Treatment with long-acting injectable antipsychotics (LAIs) reduces relapses in schizophrenia; however, best practices for introducing and transitioning patients to ...

08/20/2024

Patient Outcomes Post Hospitalization Discharge Among Patients With Schizophrenia Treated With a Long Acting Injectable or Switched to a New Oral Antipsychotic Medication

Abstract: Background: Low adherence to antipsychotic medication following a hospital discharge among patients with schizophrenia can lead to a higher risk of relapse and greater health ca...

08/20/2024

TV-46000—a Long-Acting Subcutaneous Antipsychotic (LASCA) for the Treatment of Schizophrenia: Local Tolerability and Injection Site Reactions

Abstract: Background: The phase 3 schizophrenia program for TV-46000, a long-acting subcutaneous antipsychotic (LASCA) formulation of risperidone, included the RISE efficacy study (NCT035...

08/20/2024

Patient Satisfaction With the Deutetrabenazine 4-week Patient Titration Kit: Interim Results of the
START Study

Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) for treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)-rela...

08/20/2024